Core Viewpoint - BGI Genomics announced that the total confirmed asset impairment losses and credit impairment losses for the period from January to September 2025 amount to 83.768 million yuan [2] Summary by Category - **Financial Performance** - The total confirmed asset impairment losses and credit impairment losses for the first nine months of 2025 is reported to be 83.768 million yuan [2]

Core Viewpoint - BGI Genomics (688114) reported a slight decline in revenue for the first three quarters of 2025, but managed to reduce its net loss compared to the previous year [2]. Financial Performance - The company's revenue for the first three quarters was 1.869 billion yuan, representing a year-on-year decrease of 0.01% [2]. - The net profit attributable to shareholders was -120 million yuan, indicating a reduction in losses compared to the same period last year [2]. Key Factors Influencing Performance - The reduction in net loss was primarily due to the company's ongoing efforts to reduce costs and improve efficiency, resulting in a significant decrease in expenses compared to the same period last year [2]. - Fluctuations in the exchange rates of the US dollar and euro led to an increase in foreign exchange gains from foreign currency monetary items compared to the previous year [2]. - The reversal of tax provisions related to uncertainties from previous years contributed to a decrease in income tax expenses year-on-year [2].

Major Events - Former Chairman of Beiyin Wealth Management, Fang Yi, has joined Huaxia Bank as Chief Risk Officer, pending regulatory approval [4] - Xilai Materials' subsidiary plans to invest 2 billion yuan in a semiconductor core component project, expected to generate over 1.5 billion yuan in annual output after reaching production [5][6] - Huatai Securities' subsidiary Huatai Futures has appointed Zhao Changtao as the new chairman [7] - Chuanfa Longmang's subsidiary plans to invest 366 million yuan in a 100,000 tons/year lithium dihydrogen phosphate project [8] - Huagong Technology is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] - Jiangsu Leili's actual controller has changed from Su Jianguo to both Su Jianguo and Su Da due to internal share transfers [10] - Electric Power Investment Energy has been unable to contact independent director Han Fang, but this does not affect the board's operation [11] - Qiaqia Food's subsidiary is establishing an investment company focused on the leisure food industry with a total investment of 4 billion yuan [12][13] - Steel Research High-tech plans to set up a wholly-owned subsidiary in Saudi Arabia with an investment of up to 138 million yuan [14] - Yangjie Technology has terminated the acquisition of 100% equity in Better Electronics due to differences in business types and management [15] Performance Reports - Youfa Group reported a 2320.53% increase in net profit for Q3, despite a 3.97% decline in revenue [16] - Zhuoyi Information's net profit increased by 2074.65% in Q3, with revenue growth of 2.52% [17] - North Navigation's Q3 net profit surged by 1681.27%, with a 52.12% increase in revenue [18] - Tianneng Heavy Industry's net profit grew by 1359.03% in Q3, driven by increased sales of tower tubes [19] - Te Yi Pharmaceutical's net profit rose by 985.18% in Q3, with significant growth in traditional Chinese medicine sales [20] - Hualgreen Bio's Q3 net profit increased by 619.37%, with a 35.24% rise in revenue [21] - Zhenlei Technology's net profit grew by 598.09% in Q3, supported by strong revenue growth [22] - Shengyi Electronics expects a net profit increase of 476% to 519% for the first three quarters of 2025 [23] - Glodon reported a 244.89% increase in Q3 net profit, despite a slight decline in revenue [24] - Yingli Co., Ltd. saw a 229.14% increase in Q3 net profit, with a 14.73% rise in revenue [25] - Guangkang Biochemical's Q3 net profit increased by 236.87%, despite a decline in revenue [26] - High-speed Electric's Q3 net profit rose by 242.35%, with a 44.51% increase in revenue [27] - Wide Special Materials reported a 213.65% increase in net profit for Q3, driven by improved gross margins [28] - Baofeng Energy's Q3 net profit increased by 162.34%, attributed to increased production capacity [29] - Sanfu Co., Ltd. reported a 162.25% increase in Q3 net profit, driven by improved profitability of potassium and silane products [30] - Wuku New Energy's Q3 net profit increased by 106.31%, despite a loss in the first three quarters [32] - Pioneering Technology's Q3 net profit grew by 94.01%, supported by a recovery in the household energy storage market [33] - Sanlife Guojian's net profit increased by 71.15% in Q3, driven by project collaboration and CDMO business growth [34] - BGI Genomics reported a loss of 120 million yuan in the first three quarters, despite revenue growth [35] - Rejing Bio reported a net loss of 10.9 million yuan in the first three quarters, impacted by industry policies [36] - Jiangshan Oupai reported a net loss of 51.58 million yuan in Q3, attributed to market downturns and increased competition [38] - Taiping Bird reported a net loss of 49.45 million yuan in Q3, due to declining revenue and increased inventory losses [39] - Zhongke Tongda reported a loss of 6.87 million yuan in the first three quarters, affected by project delays and market competition [40] - Wolong New Energy reported a loss of 579.7 thousand yuan in Q3, transitioning from profit to loss [41] Major Contracts - Jinggong Steel Structure signed a significant overseas project contract worth approximately 1.23 billion yuan [42][43] - New Beiyang's subsidiary won a 105 million yuan postal equipment outsourcing project [44] - Maipu Medical plans to sign product sales agency agreements with related parties, with estimated procurement amounts of 21.5 million yuan and 3.5 million yuan [45] Shareholding Changes - Yunlu Co., Ltd. shareholder Guo Keyun plans to reduce his stake by up to 3% [46] Financing - Xinda Securities has received approval from the CSRC to issue up to 10 billion yuan in technology innovation corporate bonds [47]

Core Viewpoint - The company reported a revenue of 755 million yuan for Q3 2025, marking a year-on-year increase of 14.45%, but incurred a net loss attributable to shareholders of 15.9983 million yuan [1] Financial Performance - For the first three quarters, the company achieved a revenue of 1.869 billion yuan, which represents a slight decline of 0.01% year-on-year [1] - The net loss attributable to shareholders for the first three quarters was 120 million yuan, with a basic earnings per share of -0.29 yuan [1] - The basic earnings per share for Q3 2025 was reported at -0.04 yuan [1]

Core Insights - The company reported a significant improvement in its financial performance for Q3 2025, achieving a revenue of 755 million yuan, a year-on-year increase of 14.45%, and turning a profit with a total profit change of 110.98% [1] - The overall revenue for the first three quarters of 2025 was 1.869 billion yuan, remaining stable compared to the previous year, while the net profit attributable to shareholders improved significantly, reducing losses by 74.20% to -120 million yuan [1] - The company is set to submit a technology licensing deal worth no less than 120 million USD for shareholder approval, which is expected to enhance its financial structure and global expansion [1] Financial Performance - In Q3 2025, the company achieved a revenue of 755 million yuan, marking a 14.45% increase year-on-year [1] - For the first three quarters, the company reported a revenue of 1.869 billion yuan, which is roughly flat compared to the same period last year [1] - The net profit attributable to shareholders was -120 million yuan, showing a 74.20% reduction in losses compared to the previous year [1] - Operating cash flow showed improvement, with a net outflow of approximately 208 million yuan, significantly reduced from the previous year, indicating enhanced cash generation capability [1] Cost Management - The company improved its profitability through refined operational management, with sales expenses decreasing by 13.42% to 509 million yuan and management expenses down by 23.33% to 306 million yuan [1] - The optimization of expense ratios has provided room for profit release [1] Product Innovation and Market Penetration - The company launched the ultra-high-throughput sequencer T7+ on September 9, capable of delivering over 14Tb of sequencing data within 24 hours, which is expected to drive future equipment and consumable sales [2] - The integration of AI in life sciences has progressed, with a rapid pathogen identification solution reducing detection time to 3.5 hours, demonstrating high efficiency in public health and clinical settings [2] - The intelligent automation business (GLI) generated revenue of 112 million yuan in the first half of 2025, indicating that AI integration is becoming a new growth driver for the company [2] Strategic Partnerships - The company announced a global exclusive licensing agreement with SwissRocketsAG for CoolMPS sequencing technology, which includes a minimum upfront payment of 120 million USD and milestone payments [3] - This agreement is seen as a landmark achievement for Chinese scientific instrument companies in licensing core technologies [3] - The company is expanding its ecosystem partnerships, including deepening collaboration with major institutions like Novogene and working with other firms in diagnostic kit development and microbiological testing [3]

Core Viewpoint - The company clarifies that it is not engaged in car manufacturing but rather utilizing vehicles as mobile platforms for various applications in healthcare and technology [1] Group 1: Business Focus - The company emphasizes its commitment to life science technology tools, prioritizing research and development in this area [1] - New business expansions will strictly adhere to the principles of "technical synergy and scenario extension" to maintain focus on core operations [1] Group 2: Recent Developments - The company has established "Beijing BGI Intelligent Manufacturing Technology Co., Ltd." in Beijing, with a business scope that includes software sales, automotive parts retail and wholesale, automotive sales, and sales of electronic components and electromechanical equipment [1] - The company has developed various mobile platforms equipped with its core technology, contributing significantly to public health initiatives and resource allocation in healthcare [1]

中信证券股份有限公司 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意深圳华大智造科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2022〕1638 号）同意，公司向社会公开 发行人民币普通股（A 股）41,319,475 股，发行价格为 87.18 元/股，募集资金总 额为人民币 3,602,231,830.50 元，扣除发行费用（不含增值税）317,677,388.48 元后，实际募集资金净额为 3,284,554,442.02 元。上述募集资金实际到位时间为 2022 年 9 月 6 日，已经毕马威华振会计师事务所（特殊普通合伙）审验，并出 具了《深圳华大智造科技股份有限公司 IPO 企业首次发行股票验资报告》（毕马 威华振验字第 2201281 号）。 为规范公司募集资金管理，保护投资者权益，公司对募集资金采取了专户存 储制度，上述募集资金到账后，已存放于募集资金专户，公司按规定与保荐机构、 募集资金专户监管银行签署了《募集资金专户存储三方监管协议》或《募集资金 专户存储四方监管协议》，保证募集资金监管的有效实施。 | 发行名称 | 2022 年 ...

中信证券股份有限公司 关于深圳华大智造科技股份有限公司 增加 2025 年度日常关联交易预计额度的核查意见 上海证券交易所: 1 届监事会第十四次会议审议通过了《关于 2025 年度日常关联交易调整暨增加预 计额度的议案》，关联董事汪建、牟峰、刘龙奇、余德健、朱岩梅已对此议案回 避表决。基于关联方体系范围调整、公司及子公司存在与部分关联方企业调整业 务量的情形，公司拟调整 2025 年度部分日常关联交易预计额度，其中调增向关 联方销售商品额度 590 万元；调增向关联方提供服务额度 30 万元；调增向关联 方采购服务额度 1,603 万元；并对其他支出业务的额度进行内部调整。公司本次 2025 年度日常关联交易额度调整事项无需提交公司股东大会审议。 公司于 2025 年 10 月 22 日召开了第二届董事会独立董事 2025 年第四次专门 会议，全体独立董事一致同意将《关于增加公司 2025 年度日常关联交易预计额 度的议案》提交董事会审议。同日，公司召开第二届董事会第十八次会议、第二 届监事会第十七次会议审议通过了《关于增加公司 2025 年度日常关联交易预计 额度的议案》，关联董事汪建、牟峰、刘龙奇、余德 ...

投资者关系管理制度 第一章 总 则 深圳华大智造科技股份有限公司 投资者关系管理制度 深圳华大智造科技股份有限公司 第一条 为规范深圳华大智造科技股份有限公司（以下简称"公司"）与投资 者和潜在投资者（以下合称"投资者"）之间的信息沟通，切实建立公司与投资 者（特别是社会公众投资者）的良好沟通平台，完善公司治理结构，切实保护投 资者（特别是社会公众投资者）的合法权益，形成公司与投资者之间长期、稳定、 和谐的良性互动关系，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司投资者关系管理工作指引》《上海证券交易所科创板股票上市规则》 等有关法律、法规、规范性文件以及《深圳华大智造科技股份有限公司章程》（以 下简称《公司章程》）的有关规定，结合公司实际情况，特制定本制度。 第二条 本制度所称的投资者关系管理是指公司通过便利股东权利行使、信 息披露、互动交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通， 增进投资者对公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊 重投资者、回报投资者、保护投资者目的的相关活动。 第三条 公司开展投资者关系管理工作应体现公平、公正、公开原则，平等 对待 ...

深圳华大智造科技股份有限公司 市值管理制度 第一章 总 则 第一条 为加强公司市值管理工作，进一步规范深圳华大智造科技股份有限 公司（以下简称"公司"）的市值管理行为，维护公司、投资者及其他利益相关 者的合法权益，积极响应《国务院关于进一步促进资本市场健康发展的若干意见》 中关于鼓励上市公司建立市值管理制度的号召，根据《中华人民共和国公司法》 《中华人民共和国证券法》《国务院关于加强监管防范风险推动资本市场高质量 发展的若干意见》《上市公司信息披露管理办法》《上市公司监管指引第 10 号 ——市值管理》《上海证券交易所科创板股票上市规则》及其他有关法律法规， 制订本制度。 第二条 本制度所指市值管理，是指公司以提高公司质量为基础，为提升公 司投资价值和股东回报能力而实施的战略管理行为。 第三条 公司应当牢固树立回报股东意识，采取措施保护投资者尤其是中小 投资者利益，诚实守信、规范运作、专注主业、稳健经营，以新质生产力的培育 和运用，推动经营水平和发展质量提升，并在此基础上做好投资者关系管理，增 强信息披露质量和透明度，必要时积极采取措施提振投资者信心，推动公司投资 价值合理反映公司质量。 第二章 市值管理的目 ...